Clin Case Rep Int | Volume 7, Issue 1 | Case Report | Open Access
Chiang HC1,2, Chang HJ2, Hong CT3,4* and Chan L3,4
1Department of Internal Medicine, Division of Neurology Medicine, Sinwu Branch, Taoyuan General Hospital, Ministry of Health and Welfare, Taiwan
2Department of Internal Medicine, Division of Neurology Medicine, Taoyuan General Hospital, Ministry of Health and Welfare, Taiwan
3Department of Neurology, Shuang-Ho Hospital, Taipei Medical University, Taiwan
4Department of Neurology, School of Medicine, College of Medicine, Taipei Medical University, Taiwan
*Correspondance to: Chien-Tai HongFulltext PDF
Dabigatran is one of the novel oral anticoagulants for stroke prevention in people with atrial fibrillation. Although the presence of antidote, availability, and feasibility are still challenging issues. At present, there is no conclusive recommendation regarding the post-dabigatran, non-antidoted intravenous thrombolysis for acute stroke patients. We presented a case of safely application of intravenous thrombolysis to a post-dabigatran, non-antidoted, 84-year-old female with acute nonlarge artery ischemic stroke.
Dabigatran; Antidote; Thrombolysis; Stroke
Chiang HC, Chang HJ, Hong CT, Chan L. Safety of Post-Dabigatran, Non- Antidoted Intravenous Thrombolysis for Acute Ischemic Stroke. Clin Case Rep Int. 2023; 7: 1496.